前沿速览045期| CAR-T治B淋 前沿览新知
01
优化同种异体CAR-T细胞在复发/难治性大B细胞淋巴瘤中的持久性：KIR配型的作用
Optimizing Allogeneic Chimeric Antigen Receptor T-Cell Persistence in Relapsed/Refractory Large B-Cell Lymphoma: The Role of KIR Matching
第一作者：Shimazu Y
J Clin Oncol（IF=41.9）. 2025 Jun 23:JCO2500394.
全文网址：https://ascopubs.org/doi/10.1200/JCO-25-00394?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
02
与Axicabtagene ciloleucel治疗滤泡性淋巴瘤疗效相关的临床、肿瘤及产品特征
Clinical, tumor and product features associated with outcomes after axicabtagene ciloleucel therapy in follicular lymphoma
第一作者：Poddar S
J Clin Invest（IF=13.6）. 2025 Jun 19:e181893.
全文网址：https://www.jci.org/articles/view/181893
03
结外受累对复发/难治性大B细胞淋巴瘤患者接受CAR-T细胞治疗结局的影响: 一项多中心队列研究
Impact of extranodal involvement at CAR T-cell therapy on outcomes in patients with relapsed or refractory large B-cell lymphoma-Results from a multicenter cohort study
第一作者：St-Pierre F
Blood Cancer J（IF=11.6）. 2025 Jun 21;15(1):110.
全文网址：https://pmc.ncbi.nlm.nih.gov/articles/PMC12182562/
04
弥漫大B细胞淋巴瘤在CD19 CAR-T治疗后出现跨抗原耐药性及预测CAR-T临床疗效的基因特征
DLBCL cells emerge post CD19 CAR-T with cross-antigen resistance and a gene signature predictive of clinical CAR-T response
第一作者：Lϋӧnd F
Blood Cancer Discov（IF=11.5）. 2025 Jun 27.
全文网址：https://aacrjournals.org/bloodcancerdiscov/article/doi/10.1158/2643-3230.BCD-24-0176/763370/DLBCL-cells-emerge-post-CD19-CAR-T-with-cross
05
Selinexor可减轻巨噬细胞的免疫抑制作用，并与CD19 CAR-T细胞协同抗B细胞淋巴瘤
Selinexor Reduces the Immunosuppression of Macrophages and Synergizes With CD19 CAR-T Cells Against B-Cell Lymphoma
第一作者：Luo W
Cancer Sci（IF=4.3）. 2025 Jun 17.
全文网址：https://onlinelibrary.wiley.com/doi/10.1111/cas.70123
06
基线认知和神经状态并不改变CAR-T细胞治疗侵袭性B细胞淋巴瘤中ICANS的发生
Baseline Cognitive and Neurological Status Does Not Modify the Occurrence of ICANS in CAR T-Cell Therapy for Aggressive B-Cell Lymphoma
第一作者：Ursu R
Eur J Neurol（IF=3.9）. 2025 Jun;32(6):e70236.
全文网址：https://onlinelibrary.wiley.com/doi/10.1111/ene.70236
07
脆弱非失败：合并症对接受CAR-T治疗的LBCL患者非复发死亡率及安全性的影响有限
Frail is not fail: Limited impact of comorbidities on non-relapse mortality and safety in patients with LBCL treated with CAR-T
第一作者：Galli E
Br J Haematol（IF=3.8）. 2025 Jun 23.
全文网址：https://onlinelibrary.wiley.com/doi/10.1111/bjh.20222
08
粒细胞集落刺激因子对非霍奇金淋巴瘤患者接受CAR-T细胞治疗安全性的影响
Impact of granulocyte colony-stimulating factor on safety of chimeric antigen receptor-T-cell therapy in non-Hodgkin lymphoma
第一作者：Chung K
Br J Haematol（IF=3.8）. 2025 Jun 17.
全文网址：https://onlinelibrary.wiley.com/doi/10.1111/bjh.20207
09
CD8和CD4 CAR-T细胞与tisagenlecleucel治疗CNS淋巴瘤的疗效与毒性相关
CD8 and CD4 CAR-T cells are associated with outcome and toxicity of tisagenlecleucel in central nervous system lymphoma
第一作者：Samara JA
Cytotherapy（IF=3.2）. 2025 May 24:S1465-3249(25)00714-5.
全文网址：https://www.isct-cytotherapy.org/article/S1465-3249(25)00714-5/fulltext
10
CAR-T细胞治疗相关毒性的管理策略：希腊一项调查研究结果
Management strategies for CAR-T cell therapy-related toxicities: results from a survey in Greece
第一作者：Gavriilaki E
Front Med (Lausanne)（IF=3.0）. 2025 May 30;12:1553966.
全文网址：https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1553966/full
免责声明：本资料为专业医学资料，旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参考；任何处方请参考产品最新详细处方资料。本文件可能包含涉及医学情况、健康及治疗方法的信息。相关信息不得用作诊断或治疗，不能替代专业医学意见。
审批编号：NP-NHL-2025.7-1 valid until 2027.7
供稿与审核：临床开发与医学部